CN102056607B - On01910.na促进在抗药性肿瘤中化学治疗剂的活性 - Google Patents

On01910.na促进在抗药性肿瘤中化学治疗剂的活性 Download PDF

Info

Publication number
CN102056607B
CN102056607B CN200880129775.1A CN200880129775A CN102056607B CN 102056607 B CN102056607 B CN 102056607B CN 200880129775 A CN200880129775 A CN 200880129775A CN 102056607 B CN102056607 B CN 102056607B
Authority
CN
China
Prior art keywords
gemcitabine
subject
cancer
administration
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880129775.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102056607A (zh
Inventor
A·希梅诺
M·M·伊达尔戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN102056607A publication Critical patent/CN102056607A/zh
Application granted granted Critical
Publication of CN102056607B publication Critical patent/CN102056607B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880129775.1A 2008-04-17 2008-04-17 On01910.na促进在抗药性肿瘤中化学治疗剂的活性 Expired - Fee Related CN102056607B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/005104 WO2009128805A1 (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Publications (2)

Publication Number Publication Date
CN102056607A CN102056607A (zh) 2011-05-11
CN102056607B true CN102056607B (zh) 2014-07-30

Family

ID=41199352

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880129775.1A Expired - Fee Related CN102056607B (zh) 2008-04-17 2008-04-17 On01910.na促进在抗药性肿瘤中化学治疗剂的活性

Country Status (10)

Country Link
US (2) US8962614B2 (cg-RX-API-DMAC7.html)
EP (1) EP2271339A4 (cg-RX-API-DMAC7.html)
JP (1) JP5479453B2 (cg-RX-API-DMAC7.html)
KR (1) KR101707669B1 (cg-RX-API-DMAC7.html)
CN (1) CN102056607B (cg-RX-API-DMAC7.html)
AU (1) AU2008354754B2 (cg-RX-API-DMAC7.html)
CA (1) CA2721722C (cg-RX-API-DMAC7.html)
NZ (1) NZ588749A (cg-RX-API-DMAC7.html)
RU (1) RU2476239C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009128805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008354754B2 (en) * 2008-04-17 2014-09-11 The Johns Hopkins University On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors
ES2864681T3 (es) * 2012-12-07 2021-10-14 Onconova Therapeutics Inc Tratamiento del cáncer hematológico refractario a un agente contra el cáncer
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
DK3138555T3 (da) 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
EP3263135B1 (en) 2015-02-25 2020-01-15 Bioneer Corporation Pharmaceutical composition for treating cancer comprising microrna as active ingredient
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN109232403A (zh) * 2017-07-10 2019-01-18 亚宝药业集团股份有限公司 作为蛋白激酶抑制剂的酰胺类前药衍生物
FI3811949T3 (fi) * 2018-06-20 2024-09-13 Fujifilm Corp Liposomikoostumukseen kapseloitua gemsitabiinia ja immuunitarkistuspistesalpaajaa käsittävä yhdistelmälääke
PL4048284T3 (pl) * 2019-10-21 2025-11-03 Acura Nanomedicine Corporation Metoda leczenia nowotworów
EP4479042A1 (en) 2022-02-18 2024-12-25 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
WO2008027049A1 (en) * 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070197538A1 (en) * 2004-10-07 2007-08-23 Mark Nesbit Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
US20090306207A1 (en) 2005-01-05 2009-12-10 Reddy M V Ramana Treatment of Drug-Resistant Proliferative Disorders
US7504513B2 (en) * 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
US8916552B2 (en) * 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US20080279874A1 (en) * 2007-05-07 2008-11-13 Wyeth Compositions and methods for modulation of plk1 kinase activity
AU2008354754B2 (en) * 2008-04-17 2014-09-11 The Johns Hopkins University On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
WO2008027049A1 (en) * 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gumireddy K et al.ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.《CANCER CELL》.2005,第7卷275-286. *
STREBHARDT K et al.Targeting polo-like kinase 1 for cancer therapy.《 NATURE REVIEWS. CANCER》.2006,第6卷(第4期),321-330. *

Also Published As

Publication number Publication date
EP2271339A4 (en) 2011-09-28
EP2271339A1 (en) 2011-01-12
CA2721722A1 (en) 2009-10-22
JP5479453B2 (ja) 2014-04-23
AU2008354754B2 (en) 2014-09-11
CA2721722C (en) 2015-12-08
US8962614B2 (en) 2015-02-24
WO2009128805A1 (en) 2009-10-22
US20110201675A1 (en) 2011-08-18
AU2008354754A1 (en) 2009-10-22
RU2476239C2 (ru) 2013-02-27
RU2010145048A (ru) 2012-05-27
CN102056607A (zh) 2011-05-11
JP2011518153A (ja) 2011-06-23
NZ588749A (en) 2012-06-29
KR101707669B1 (ko) 2017-02-16
US20150209381A1 (en) 2015-07-30
KR20100137570A (ko) 2010-12-30
US9545418B2 (en) 2017-01-17

Similar Documents

Publication Publication Date Title
CN102056607A (zh) On01910.na促进在抗药性肿瘤中化学治疗剂的活性
ES2882223T3 (es) 17Alfa-valerato de cortexolona para el uso en el tratamiento de tumores
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
ES2881928T3 (es) Profármacos de etopósido para su uso en el direccionamiento a las células madre cancerosas
CN108136207A (zh) 用于治疗癌症的联合疗法
CA3044880C (en) Cannabinoids for the preventive treatment of unintentional weight loss
JP2019513812A (ja) 化学療法の改善
TWI771344B (zh) 一種vegfr抑制劑與parp抑制劑聯合在製備治療胃癌的藥物中的用途
CA2980885A1 (en) Glycolipids and pharmaceutical compositions thereof for use in therapy
CA3017552A1 (en) Combination therapy for proliferative diseases
WO2013085902A1 (en) Combination therapy methods for treating an inflammatory breast cancer
US12319915B2 (en) Cytotoxic fluoropyrimidine polymers and methods of use thereof
US20250360157A1 (en) Cytotoxic fluoropyrimidine polymers and methods of use thereof
US20250170096A1 (en) Oxphos inhibitors for use in treating cancer
GB2504550A (en) Diarylurea compound PQ401 for inhibiting the growth and/or proliferation of cancer stem cells
HK1138797A (zh) 肝癌治疗剂
HK1178458A (en) Therapeutic agent for liver cancer
JP2019064975A (ja) 抗がん剤
HK1202419B (en) Combination therapy with a mitotic inhibitor
WO2015157172A1 (en) Combination therapies with curaxins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140730

Termination date: 20180417